FAIL FORWARD AND PIVOT
Traditional Vaccine Platforms:
• Modified Live Attenuated Vaccine: Bavarian Nordic A/S will modify its BN-MVA platform vaccine, the back- bone of the FDA-approved JYNNEOS smallpox vaccine and mainstay of the nation’s strategic national stockpile, for prevention of three equine encephalitis viruses (Vene- zuelan, Eastern and Western).
• mRNA: The University of Texas Medical Branch (UTMB), in partnership with Moderna Inc., will build on their success in developing a bivalent COVID-19 vaccine by applying their mRNA platform to hemor- rhagic fever viruses, including Ebola Zaire, Ebola Sudan, Marburg and Lassa fever viruses. Additionally, Astra- Zeneca will further develop its mRNA platform for protection against pandemic avian influenzas.
• saRNA: Two efforts, the Access to Advanced Health Institute and UTMB in partnership with HDT Bio, will further develop self-amplifying RNA (saRNA) vaccines, a more recently developed technology, against pandemic avian influenzas, henipaviruses and Crimean Congo hemorrhagic fever virus. Te saRNA vaccines aim to improve the immune response to mRNA vaccines while increasing their safety profile.
Immune Modulator Platforms:
• Cytosine-Phosphate-Guanosine Oligodeoxynucle- otide: Dynavax Technologies will conduct a Phase II human clinical trial with its novel immune modulator platform cytosine-phosphate-guanosine 1018, a toll-like receptor agonist, co-administered with DOD’s Plague Vaccine rF1V, to improve the utility of the plague vaccine for rapid response.
• Toll-like Receptor Agonists: ENA Respiratory and the Access to Advanced Health Institute are independently developing a self-administered dry powder nasal spray for the prevention of common and emerging respiratory viral threats. Both products are designed for rapid protec- tion and use in austere environments.
Te utilization of platforms significantly reduces development time for future efforts by altering only minor portions of vaccines to address new targets. By targeting development of proven platforms, the program supports the creation of an agile phar- maceutical industry with the tools and technologies necessary to rapidly shift design and manufacturing of vaccine candidates from current to emerging threats, in near-real time.
COMING TOGETHER JPM CBRN Medical, BARDA and UTMB personnel during a UTMB site visit. (Photo by Sarah Murtaza, BARDA)
72
Army AL&T Magazine
Fall 2023
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136
